Last10K.com

Adamas Pharmaceuticals Inc (ADMS) SEC Filing 10-K Annual report for the fiscal year ending Thursday, December 31, 2020

Adamas Pharmaceuticals Inc

CIK: 1328143 Ticker: ADMS
Exhibit 99.1

Adamas Reports Fourth Quarter and Full Year 2020 Financial Results
Fourth Quarter 2020 total revenues of $21.0 million, a 29% increase over fourth quarter 2019
Full Year 2020 total revenues of $74.5 million, a 36% increase over 2019
Second indication received February 2021 for GOCOVRI as an adjunctive treatment to levodopa/carbidopa in Parkinson’s disease patients experiencing OFF episodes

EMERYVILLE, Calif., February 23, 2021 -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today reported financial results for the fourth quarter and full year ended December 31, 2020, and recent corporate highlights.
“We are excited with the opportunities ahead of us, including the continued growth of GOCOVRI which is now the first and only medication approved to treat both OFF and dyskinesia motor complications in Parkinson’s disease,” said Neil F. McFarlane, Chief Executive Officer. “Bolstered by the launch of a second indication, GOCOVRI is now approved to treat approximately 400,000 to 500,000 Parkinson’s patients. The significant progress made across the business in 2020 fueled positive momentum into 2021, and we are leveraging this as we continue to successfully execute our long-term growth strategy.”
Recent portfolio highlights
Total revenues were $21.0 million in the fourth quarter of 2020, an increase of 29% as compared to $16.3 million in the fourth quarter of 2019.
GOCOVRI® (amantadine) extended release capsules product sales were $19.8 million in the fourth quarter of 2020, an increase of 21% as compared to $16.3 million in the fourth quarter of 2019.
Total paid prescriptions (TRx) of GOCOVRI were approximately 8,165 in the fourth quarter of 2020, a 14% increase over approximately 7,160 TRx in the fourth quarter of 2019.
Strong patient persistence of 45%-50% at 12 months continued in the fourth quarter of 2020.
New paid prescriptions (NRx) of GOCOVRI were approximately 510 in the fourth quarter of 2020, a 19% increase over NRx of approximately 430 in the third quarter of 2020.
In February 2021, the U.S. Food and Drug Administration approved a second indication for GOCOVRI as an adjunctive treatment to levodopa/carbidopa in Parkinson’s disease patients experiencing OFF episodes.
Corporate highlights
In January 2021, closed the settlement of patent litigation with Osmotica Pharmaceuticals plc. and completed the acquisition of the global rights to OSMOLEX ER® (amantadine) extended release tablets, expanding Adamas’ neurology portfolio.
Amended certain key terms of the Royalty-Backed Loan agreement with HealthCare Royalty Partners, which became effective with the closing of the acquisition of OSMOLEX ER.
In February 2021, announced a settlement agreement with Zydus Worldwide DMCC and Zydus Pharmaceuticals (USA) Inc. (“Zydus”) resolving patent litigation between the two parties relating to Zydus’ ANDA referencing GOCOVRI. Under the agreement Adamas granted Zydus a non-exclusive license to begin selling a generic version of GOCOVRI as of March 4, 2030, or earlier in certain circumstances.


The following information was filed by Adamas Pharmaceuticals Inc (ADMS) on Tuesday, February 23, 2021 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Adamas Pharmaceuticals Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Adamas Pharmaceuticals Inc.

Continue

Assess how Adamas Pharmaceuticals Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Adamas Pharmaceuticals Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Rating

Learn More
Bullish Bearish Neutral
Filter by Sentiment:
All
Positive
Negative
Filter by Category:
All
Financial
Revenue
Mgmt Change
Other
Filter by Subcategory:
All
Expense
Product
Income
Cash Flow
Shares
Other
Inside Adamas Pharmaceuticals Inc's 10-K Annual Report:

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Cover Page
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Comprehensive Loss
Consolidated Statements Of Operations
Consolidated Statements Of Stockholders??? Equity (Deficit)
Balance Sheet Components
Balance Sheet Components (Details)
Balance Sheet Components (Tables)
Basis Of Presentation And Summary Of Significant Accounting Policies
Basis Of Presentation And Summary Of Significant Accounting Policies (Policies)
Basis Of Presentation And Summary Of Significant Accounting Policies (Tables)
Basis Of Presentation And Summary Of Significant Accounting Policies - Concentration Of Risk (Details)
Basis Of Presentation And Summary Of Significant Accounting Policies - Liquidity (Details)
Basis Of Presentation And Summary Of Significant Accounting Policies - Property And Equipment (Details)
Basis Of Presentation And Summary Of Significant Accounting Policies - Segments (Details)
Commitments And Contingencies
Commitments And Contingencies (Details)
Convertible Preferred Stock
Convertible Preferred Stock (Details)
Description Of Business
Description Of Business (Details)
Fair Value Measurements
Fair Value Measurements (Tables)
Fair Value Measurements - Changes In Estimated Fair Value Of Embedded Derivative (Details)
Fair Value Measurements - Financial Assets And Liabilities Which Require Fair Value Measurement (Details)
Fair Value Measurements - Narrative (Details)
Income Taxes
Income Taxes (Tables)
Income Taxes - Additional Information (Details)
Income Taxes - Provision For Income Taxes (Details)
Income Taxes - Uncertain Tax Positions (Details)
Inventory
Inventory (Details)
Inventory (Tables)
Investments
Investments (Details)
Investments (Tables)
Leases
Leases (Tables)
Leases - Balance Sheet Classification Of Operating Lease Liabilities (Details)
Leases - Components Of Lease Costs (Details)
Leases - Maturities Of Operating Lease Liabilities (Details)
Leases - Narrative (Details)
License Agreements
License Agreements (Details)
Long-Term Debt
Long-Term Debt (Tables)
Long-Term Debt - Long-Term Debt And Unamortized Debt Discount Balances (Details)
Long-Term Debt - Narrative (Details)
Net Loss Per Share
Net Loss Per Share (Details)
Net Loss Per Share (Tables)
Stock-Based Compensation
Stock-Based Compensation (Tables)
Stock-Based Compensation - Employee Stock Purchase Plan (Details)
Stock-Based Compensation - Non-Employee Stock-Based Compensation (Details)
Stock-Based Compensation - Restricted Stock Unit Activity (Details)
Stock-Based Compensation - Stock Compensation Plans (Details)
Stock-Based Compensation - Stock Option Activity (Details)
Stock-Based Compensation - Stock-Based Compensation Expense (Details)
Stock-Based Compensation - Weighted Average Assumptions (Details)
Stockholders??? Equity
Stockholders??? Equity (Details)
Stockholders??? Equity (Tables)
Subsequent Events
Subsequent Events (Details)
Ticker: ADMS
CIK: 1328143
Form Type: 10-K Annual Report
Accession Number: 0001328143-21-000019
Submitted to the SEC: Tue Feb 23 2021 4:01:07 PM EST
Accepted by the SEC: Tue Feb 23 2021
Period: Thursday, December 31, 2020
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/adms/0001328143-21-000019.htm